Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | PTK2 | Q05397 | 7/20 | 0.41 |
| ▸ | TOP2A | P11388 | 2/20 | 0.41 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | KHK | P50053 | 1/20 | 0.38 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5788221 | 0.90 | PTK2 (0.40) | SMYD3PTK2TOP2ASRD5A2NPC1 | |
| SCHEMBL914662 | 0.85 | PARP1 (0.48) | PARP1 | |
| SCHEMBL6963683 | 0.81 | KMT2A (0.37) | RAB9APARP1KMT2A | |
| SCHEMBL915005 | 0.81 | SRD5A2 (0.61) | HTR2AHTR2CSLC6A4HTR2BSRD5A2 | |
| SCHEMBL914803 | 0.80 | L3MBTL1 (0.44) | HTR2AHTR2CSLC6A4HTR2BSRD5A2 | |
| SCHEMBL914072 | 0.79 | SMYD3 (0.47) | SMYD3SRD5A2NPC1POLBRAB9A | |
| Hydrochloric Acid SCHEMBL916268 | 0.78 | SMYD3 (0.46) | SMYD3SRD5A2NPC1POLBRAB9A | |
| SCHEMBL914457 | 0.77 | SMYD3 (0.44) | SMYD3SRD5A2NPC1POLBRAB9A | |
| SCHEMBL914691 | 0.77 | SRD5A2 (0.47) | SMYD3TOP2ASRD5A2NPC1POLB | |
| SCHEMBL5785835 | 0.76 | PARP1 (0.46) | PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183366-B2 | Chemokine receptor antagonists | NOVARTIS AG (CH) | 2012-05-22 | — | — | US | disclosed |
| US-20110015180-A1 | Chemokine receptor antagonists | NOVARTIS AG (CH) | 2011-01-20 | — | — | US | disclosed |
| US-7858781-B2 | Chemokine receptor antagonists | NOVARTIS AG (CH) | 2010-12-28 | — | — | US | disclosed |
| EP-1720859-B1 | CHEMOKINE RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2009-12-23 | — | — | EP | disclosed |
| US-20070155721-A1 | Chemokine receptor antagonists | NOVARTIS AG (CH) | 2007-07-05 | — | — | US | disclosed |
| EP-1720859-A2 | CHEMOKINE RECEPTOR ANTAGONISTS | Novartis AG (CH) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005077932-A2 | CHEMOKINE RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2005-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015180-A1 | Chemokine receptor antagonists | ACKR3, CXCR2, CXCR4 | SMYD3 3615/4885HTR2A 1347/4885HTR2C 2074/4885 |
| US-20070155721-A1 | Chemokine receptor antagonists | ACKR3, CXCR2, CXCR4 | SMYD3 3572/4885HTR2A 1370/4885HTR2C 2053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.